Project Grant R21CA299377
Award Date
3/1/25
Completion Date
2/28/27
Dollars Obligated
$230K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms driving acquired cross-resistance in small cell lung cancer (SCLC). The $642,429 award to the University of Texas Southwestern Medical Center, effective January 1, 2025 through December 31, 2029, aims to investigate how extrachromosomal MYC amplifications contribute to broad chemotherapy resistance in SCLC patient-derived...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $3,787,956 to New York University School of Medicine to investigate and develop strategies for targeting replication stress in small cell lung cancer (SCLC). The research aims to: 1) understand how the protein SLFN11 informs chemo-responsiveness in SCLC subtypes, 2) study how replication stress response pathways and modulators regulate chemo-sensitivity, and 3) integrate these insights to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This $160,330 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of novel human-relevant lung adenocarcinoma models at the University of Illinois. The goal is to create organoid and xenograft models by genome editing primary human lung stem and progenitor cells to better capture the initiation, progression, and composition of primary human lung tumors compared to current mouse models. The research aims to characterize...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $701,538 to the Icahn School of Medicine at Mount Sinai to investigate the lineage evolution and epigenomic signatures of a distinct subtype of small cell lung cancer (SCLC) characterized by the lineage factor NKX2-1. The research aims to: 1) Determine how cell-of-origin and NKX2-1 impact the evolution and maintenance of this SCLC epigenomic subtype, 2) Elucidate the...
The National Cancer Institute (NCI) awarded a $1,592,358 Project Grant (CFDA 93.396 Cancer Biology Research) to The Leland Stanford Junior University (Stanford University) to conduct research on modulating cysteine metabolism to induce cell death in small cell lung cancer (SCLC). The project aims to determine how cysteine deprivation triggers cell state-specific lethal mechanisms in SCLC cells, focusing on the role of the GCN2/ATF4 amino acid sensing pathway, polyunsaturated phospholipid...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $164,500 to The Trustees of Columbia University in the City of New York to investigate the mechanisms by which the protein S100A9 mediates brain metastasis in epidermal growth factor receptor (EGFR)-mutant lung cancer. The key goals are to: Examine how S100A9 expression is epigenetically regulated by histone methylation and the MEIS1 transcription factor in brain metastasis-prone cells....
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $705,263 to Northwestern University to conduct research on the transformation of lung adenocarcinoma to small cell lung cancer. The 3-year award, which runs from September 2024 to September 2027, will involve single-cell tracking to better understand this disease progression. This research aims to advance scientific understanding...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a new monoclonal antibody-based therapeutic tool to treat small cell lung cancer (SCLC). The $194,013 award to the University of Southern California will fund two key objectives: 1) generation of a mouse monoclonal antibody specifically targeting an abnormal isoaspartylated form of the ELAVL4 protein found on SCLC tumors, and 2) testing the therapeutic efficacy of this antibody...